

MicroRNA Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

Market Report | 2023-07-28 | 255 pages | Infinium Global Research and Consulting Solutions

AVAILABLE LICENSES:

- 1-5 User \$4795.00
- Enterprise \$7195.00

Report description:

The report on the global microRNA market provides qualitative and quantitative analysis for the period from 2021-2030. The revenue generated by the market was USD 1224.89 Million in 2022 and is expected to reach USD 2977.79 Million in 2030, with a CAGR of 12.25% till 2030 during the projected period.

The class of tiny, highly conserved non-coding RNA molecules known as microRNAs (miRNAs) is essential for the control of gene expression. RNA polymerases II and III transcribe them, producing precursors that go through a series of cleavage events to become mature miRNAs. These mature miRNAs are typically 18-25 nucleotides in length. Unlike traditional coding RNAs, miRNAs do not encode proteins. Instead, they function as post-transcriptional regulators of gene expression. By binding to messenger RNAs (mRNAs), miRNAs can modulate the functions of other genes involved in protein synthesis. They act by either inhibiting mRNA translation or promoting mRNA degradation, thereby fine-tuning gene expression levels. The market for miRNAs is experiencing growth driven by the increasing number of clinical trials targeting chronic diseases.

Cancer is to experience dominance in the application segment of the microRNA (miRNA) market. miRNAs have demonstrated tremendous promise in the study of diagnosis, prognosis, and therapy of cancer. Due to significant investments in cancer research and the adoption of miRNA signatures, the highest revenue share was achieved. MicroRNAs (miRNAs) have various advantages over invasive testing and show potential as diagnostic biomarkers for cancer. They can be found in a variety of biofluids, such as blood, urine, and tissue samples, making it possible to use quick and simple testing procedures. The existence of particular miRNA signatures can offer important insights into cancer risk assessment, early cancer detection, and cancer subtype distinction. Healthcare providers can increase the accuracy of cancer detection and hence improve patient outcomes by utilizing miRNA profiles.

North America is to experience dominance in the region segment in the global microRNA (miRNA) market due to several key factors. The region's dominance is driven by the presence of key players and a strong research and development (R&D) infrastructure in the life sciences and biotechnology sectors. With leading academic institutions, research organizations, and biotech companies making substantial investments in miRNA research, North America has witnessed scientific advancements and fostered innovation in the field. Furthermore, North America, particularly the United States, boasts one of the highest healthcare expenditures worldwide. This significant investment in healthcare infrastructure, research, and development further propels the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

growth of the miRNA market in the region. The availability of substantial financial resources enables healthcare providers to adopt advanced diagnostic technologies and therapies, including miRNA-based approaches. Collaboration and partnerships between academic institutions, industry players, and research organizations also play a crucial role in North America's dominance. These collaborative efforts facilitate knowledge exchange, technology transfer, and the commercialization of miRNA-based products. The region's strong culture of collaboration accelerates research and development, leading to market growth.

Report Findings

1) Drivers

- The market is experiencing growth as more clinical trials for chronic diseases are conducted.
- The market for miRNA-based products and services is driven by the need for precise and early diagnosis, as well as for tailored therapeutics.

2) Restraints

- The factor which restrains the market growth is safety and toxicity issues in the services.

3) Opportunities

- The advancement in the technology creates an opportunity in the market, the discovery of novel miRNAs, identification of miRNA targets, and characterization of miRNA function are all made possible by Next-generation Sequencing (NGS) techniques.

Research Methodology

A) Primary Research

Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include

1. Key Opinion Leaders associated with Infinium Global Research
2. Internal and External subject matter experts
3. Professionals and participants from the industry

Our primary research respondents typically include

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global microRNA market is segmented on the basis of product and service, application, and end user.

The Global MicroRNA Market by Product and Service

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Profiling
- Localization
- Quantification

The Global MicroRNA Market by Application

- Cancer
- Neurological Disease

The Global MicroRNA Market by End User

- Pharma & Biotech Companies
- Academic & Research Institutes
- Healthcare Facilities
- Others

Company Profiles

The companies covered in the report include

- Merck KGaA
- Thermo Fisher Scientific Inc.
- Horizon Discovery Ltd.
- QIAGEN
- GeneCopoeia, Inc.
- New England Biolabs
- Quantabio
- NanoString Technologies, Inc.
- BioGenex
- SeqMatic LLC.

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the microRNA market.
2. Complete coverage of all the segments in the microRNA market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global microRNA market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Table of Contents:

Table of Content

Chapter 1. Preface

- 1.1.□Report Description
- 1.2.□Research Methods
- 1.3.□Research Approaches

Chapter 2. Executive Summary

- 2.1.□MicroRNA Market Highlights
- 2.2.□MicroRNA Market Projection
- 2.3.□MicroRNA Market Regional Highlights

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Chapter 3. Global MicroRNA Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.3. Porter's Five Forces Analysis

3.4. IGR-Growth Matrix Analysis

3.4.1. IGR-Growth Matrix Analysis by Product and Service

3.4.2. IGR-Growth Matrix Analysis by Application

3.4.3. IGR-Growth Matrix Analysis by End User

3.4.4. IGR-Growth Matrix Analysis by Region

3.5. Value Chain Analysis of MicroRNA Market

Chapter 4. MicroRNA Market Macro Indicator Analysis

Chapter 5. Global MicroRNA Market by Product and Service

5.1. Profiling

5.2. Localization

5.3. Quantification

Chapter 6. Global MicroRNA Market by Application

6.1. Cancer

6.2. Neurological Disease

Chapter 7. Global MicroRNA Market by End User

7.1. Pharma & Biotech Companies

7.2. Academic & Research Institutes

7.3. Healthcare Facilities

7.4. Others

Chapter 8. Global MicroRNA Market by Region 2023-2030

8.1. North America

8.1.1. North America MicroRNA Market by Product and Service

8.1.2. North America MicroRNA Market by Application

8.1.3. North America MicroRNA Market by End User

8.1.4. North America MicroRNA Market by Country

8.1.4.1. The U.S. MicroRNA Market

8.1.4.1.1. The U.S. MicroRNA Market by Product and Service

8.1.4.1.2. The U.S. MicroRNA Market by Application

8.1.4.1.3. The U.S. MicroRNA Market by End User

8.1.4.2. Canada MicroRNA Market

8.1.4.2.1. Canada MicroRNA Market by Product and Service

8.1.4.2.2. Canada MicroRNA Market by Application

8.1.4.2.3. Canada MicroRNA Market by End User

8.1.4.3. Mexico MicroRNA Market

8.1.4.3.1. Mexico MicroRNA Market by Product and Service

8.1.4.3.2. Mexico MicroRNA Market by Application

8.1.4.3.3. Mexico MicroRNA Market by End User

8.2. Europe

8.2.1. Europe MicroRNA Market by Product and Service

8.2.2. Europe MicroRNA Market by Application

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2.3.□Europe MicroRNA Market by End User
- 8.2.4.□Europe MicroRNA Market by Country
 - 8.2.4.1.□Germany MicroRNA Market
 - 8.2.4.1.1.□Germany MicroRNA Market by Product and Service
 - 8.2.4.1.2.□Germany MicroRNA Market by Application
 - 8.2.4.1.3.□Germany MicroRNA Market by End User
 - 8.2.4.2.□United Kingdom MicroRNA Market
 - 8.2.4.2.1.□United Kingdom MicroRNA Market by Product and Service
 - 8.2.4.2.2.□United Kingdom MicroRNA Market by Application
 - 8.2.4.2.3.□United Kingdom MicroRNA Market by End User
 - 8.2.4.3.□France MicroRNA Market
 - 8.2.4.3.1.□France MicroRNA Market by Product and Service
 - 8.2.4.3.2.□France MicroRNA Market by Application
 - 8.2.4.3.3.□France MicroRNA Market by End User
 - 8.2.4.4.□Italy MicroRNA Market
 - 8.2.4.4.1.□Italy MicroRNA Market by Product and Service
 - 8.2.4.4.2.□Italy MicroRNA Market by Application
 - 8.2.4.4.3.□Italy MicroRNA Market by End User
 - 8.2.4.5.□Rest of Europe MicroRNA Market
 - 8.2.4.5.1.□Rest of Europe MicroRNA Market by Product and Service
 - 8.2.4.5.2.□Rest of Europe MicroRNA Market by Application
 - 8.2.4.5.3.□Rest of Europe MicroRNA Market by End User
- 8.3.□Asia Pacific
 - 8.3.1.□Asia Pacific MicroRNA Market by Product and Service
 - 8.3.2.□Asia Pacific MicroRNA Market by Application
 - 8.3.3.□Asia Pacific MicroRNA Market by End User
 - 8.3.4.□Asia Pacific MicroRNA Market by Country
 - 8.3.4.1.□China MicroRNA Market
 - 8.3.4.1.1.□China MicroRNA Market by Product and Service
 - 8.3.4.1.2.□China MicroRNA Market by Application
 - 8.3.4.1.3.□China MicroRNA Market by End User
 - 8.3.4.2.□Japan MicroRNA Market
 - 8.3.4.2.1.□Japan MicroRNA Market by Product and Service
 - 8.3.4.2.2.□Japan MicroRNA Market by Application
 - 8.3.4.2.3.□Japan MicroRNA Market by End User
 - 8.3.4.3.□India MicroRNA Market
 - 8.3.4.3.1.□India MicroRNA Market by Product and Service
 - 8.3.4.3.2.□India MicroRNA Market by Application
 - 8.3.4.3.3.□India MicroRNA Market by End User
 - 8.3.4.4.□South Korea MicroRNA Market
 - 8.3.4.4.1.□South Korea MicroRNA Market by Product and Service
 - 8.3.4.4.2.□South Korea MicroRNA Market by Application
 - 8.3.4.4.3.□South Korea MicroRNA Market by End User
 - 8.3.4.5.□Australia MicroRNA Market
 - 8.3.4.5.1.□Australia MicroRNA Market by Product and Service
 - 8.3.4.5.2.□Australia MicroRNA Market by Application
 - 8.3.4.5.3.□Australia MicroRNA Market by End User

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.4.6. Rest of Asia-Pacific MicroRNA Market
 - 8.3.4.6.1. Rest of Asia-Pacific MicroRNA Market by Product and Service
 - 8.3.4.6.2. Rest of Asia-Pacific MicroRNA Market by Application
 - 8.3.4.6.3. Rest of Asia-Pacific MicroRNA Market by End User
- 8.4. RoW
 - 8.4.1. RoW MicroRNA Market by Product and Service
 - 8.4.2. RoW MicroRNA Market by Application
 - 8.4.3. RoW MicroRNA Market by End User
 - 8.4.4. RoW MicroRNA Market by Sub-region
 - 8.4.4.1. Latin America MicroRNA Market
 - 8.4.4.1.1. Latin America MicroRNA Market by Product and Service
 - 8.4.4.1.2. Latin America MicroRNA Market by Application
 - 8.4.4.1.3. Latin America MicroRNA Market by End User
 - 8.4.4.2. Middle East MicroRNA Market
 - 8.4.4.2.1. Middle East MicroRNA Market by Product and Service
 - 8.4.4.2.2. Middle East MicroRNA Market by Application
 - 8.4.4.2.3. Middle East MicroRNA Market by End User
 - 8.4.4.3. Africa MicroRNA Market
 - 8.4.4.3.1. Africa MicroRNA Market by Product and Service
 - 8.4.4.3.2. Africa MicroRNA Market by Application
 - 8.4.4.3.3. Africa MicroRNA Market by End User
- Chapter 9. Company Profiles and Competitive Landscape
 - 9.1. Competitive Landscape in the Global MicroRNA Market
 - 9.2. Companies Profiles
 - 9.2.1. Merck KGaA
 - 9.2.2. Thermo Fisher Scientific Inc.
 - 9.2.3. Horizon Discovery Ltd.
 - 9.2.4. QIAGEN
 - 9.2.5. GeneCopoeia, Inc.
 - 9.2.6. New England Biolabs
 - 9.2.7. Quantabio
 - 9.2.8. NanoString Technologies, Inc.
 - 9.2.9. BioGenex
 - 9.2.10. SeqMatic LLC.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MicroRNA Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

Market Report | 2023-07-28 | 255 pages | Infinium Global Research and Consulting Solutions

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	1-5 User	\$4795.00
	Enterprise	\$7195.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-04"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com